Redwood Pharma’s innovative dry eye treatment to be presented at ARVO in Seattle

Stockholm, February 28, 2024. Redwood Pharma AB (publ) announces today that a poster summarizing the company’s clinical study with the innovative treatment of dry eye, RP501, has been accepted to the annual conference Association for Research in Vision and Ophthalmology, ARVO, in Seattle, United States, May 5-9, 2024.

Redwood Pharma will participate in one of the world’s largest conferences in the field of ophthalmology, The Association for Research in Vision and Ophthalmology, ARVO, which will take place in Seattle, USA, on May 5-9. The conference brings together around 10,000 researchers and clinicians in the field of ophthalmology from around the world, as well as representatives of global and regional pharmaceutical and medtech companies.

“We are delighted to have the opportunity to present our clinical results on RP501 at the world’s largest forum where researchers and industry meet to discuss innovations in eye care; it also gives us an excellent opportunity for partner discussions”, says Martin Vidaeus, CEO of Redwood Pharma.

Assoc. Prof. Gerhard Garhöfer at the Medizinische Universität Wien, Austria, who was clinically responsible for the study and is the author of the publication, will present a poster entitled: “Assessment of safety, tolerability and efficacy of RP501 eye drops in patients with dry eye disease and subjects wearing contact lenses with lens discomfort”. The poster summarizes the completed clinical study with the company’s medical technology product RP501.

RP501 is being developed to be an effective and user-friendly over-the-counter tear replacement agent for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The clinical results from the RP501 study showed significant therapeutic effect and ease of use – two characteristics that, according to market research, are considered to be the most important parameters for a product against dry eyes.

“Significant efficacy, safety and tolerability results together with the fact that a clear majority of patients in the clinical trial responded positively to the product strengthen the potential for successful development and commercialization of new products based on the IntelliGel platform. In addition to RP501, there are great opportunities to develop new IntelliGel -based products,” says Gerhard Garhöfer.

In addition to RP501, Redwood Pharma is also developing RP101, a new potential treatment for postmenopausal women suffering from moderate to severe dry eye and combined with estrogen. Both RP501 and RP101 are based on IntelliGel – a patented and unique formulation that has the consistency of a drop of water when instilled into the eye but immediately transforms into a viscous, protective and lubricating film that remains in the eye for a long time.

For more information:

Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29

About Redwood Pharma

Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today’s standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma’s programs are based on IntelliGel – a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, For more information, visit